PharmacoEconomics & Outcomes News

, Volume 821, Issue 1, pp 17–17 | Cite as

IDegLira good value for money in T2DM in Czech Republic

Clinical study


  1. Pohlmann J, et al. Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi. Diabetes Therapy : 31 Jan 2019. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations